Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 25Rectal Neoplasms 23Esophageal Neoplasms 22Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 16Pancreatic Neoplasms 14Lung Neoplasms 14Head and Neck Neoplasms 12Colorectal Neoplasms 11Sarcoma 10Brain Neoplasms 10Neoplasms 9Colonic Neoplasms 8Adenocarcinoma Of Esophagus 7Melanoma 6Glioma 6Esophageal Squamous Cell Carcinoma 6Ovarian Neoplasms 5Oropharyngeal Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Prostatic Neoplasms 4Mouth Neoplasms 4Gliosarcoma 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Squamous Cell 4

Interventions

pyrotinib 1pertuzumab 1Trastuzumab 1Surgical Procedures, Operative 1Mastectomy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Invasive × Surgical Procedures, Operative × Clear all
NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
216 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡